CASTLE ROCK, CO--(MARKET WIRE)--Mar 12, 2009 -- AspenBio Pharma, Inc. (NasdaqCM:APPY - News), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, today reported additional information and planned next steps for advancing its AppyScore(TM) product through the Food and Drug Administration (“FDA”) application and clearance process following the recently completed pivotal clinical trial. AppyScore(TM) is the world’s first blood-based test being developed as an aid in the diagnosis of human appendicitis. Based upon the assessment to date, the following key points are made:
